204 related articles for article (PubMed ID: 34128484)
1. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers.
Compérat E; Amin MB; Epstein JI; Hansel DE; Paner G; Al-Ahmadie H; True L; Bayder D; Bivalacqua T; Brimo F; Cheng L; Cheville J; Dalbagni G; Falzarano S; Gordetsky J; Guo C; Gupta S; Hes O; Iyer G; Kaushal S; Kunju L; Magi-Galluzzi C; Matoso A; McKenney J; Netto GJ; Osunkoya AO; Pan CC; Pivovarcikova K; Raspollini MR; Reis H; Rosenberg J; Roupret M; Shah RB; Shariat SF; Trpkov K; Weyerer V; Zhou M; Reuter V
Adv Anat Pathol; 2021 Jul; 28(4):196-208. PubMed ID: 34128484
[TBL] [Abstract][Full Text] [Related]
2. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia.
Amin MB; Comperat E; Epstein JI; True LD; Hansel D; Paner GP; Al-Ahmadie H; Baydar D; Bivalacqua T; Brimo F; Cheng L; Cheville J; Dalbagni G; Falzarano S; Gordetsky J; Guo CC; Gupta S; Hes O; Iyer G; Kaushal S; Kunju L; Magi-Galluzzi C; Matoso A; Netto G; Osunkoya AO; Pan CC; Pivovarcikova K; Raspollini MR; Reis H; Rosenberg J; Roupret M; Shah RB; Shariat S; Trpkov K; Weyerer V; Zhou M; McKenney J; Reuter VE
Adv Anat Pathol; 2021 Jul; 28(4):179-195. PubMed ID: 34128483
[TBL] [Abstract][Full Text] [Related]
3. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers: Erratum.
Adv Anat Pathol; 2022 Jan; 29(1):47. PubMed ID: 34879039
[No Abstract] [Full Text] [Related]
4. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.
Gevaert T; Cimadamore A; Eckstein M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Future Oncol; 2019 Jul; 15(19):2199-2202. PubMed ID: 31213082
[No Abstract] [Full Text] [Related]
5. Molecular Pathology of Urothelial Carcinoma.
Al-Ahmadie H; Netto GJ
Clin Lab Med; 2024 Jun; 44(2):181-198. PubMed ID: 38821640
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
Pierconti F; Raspollini MR; Martini M; Larocca LM; Bassi PF; Bientinesi R; Baroni G; Minervini A; Petracco G; Pini GM; Patriarca C
Virchows Arch; 2020 Aug; 477(2):269-277. PubMed ID: 32034486
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
8. pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging.
Raspollini MR; Montironi R; Mazzucchelli R; Cimadamore A; Cheng L; Lopez-Beltran A
Virchows Arch; 2020 Jul; 477(1):3-16. PubMed ID: 32296929
[TBL] [Abstract][Full Text] [Related]
9. News in the classification of WHO 2022 bladder tumors.
Raspollini MR; Comperat EM; Lopez-Beltran A; Montironi R; Cimadamore A; Tsuzuki T; Netto GJ
Pathologica; 2022 Feb; 115(1):32-40. PubMed ID: 36704871
[TBL] [Abstract][Full Text] [Related]
10. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zschäbitz S; Niegisch G
Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
13. A new era in the treatment of urothelial carcinoma.
Faltas B
Urol Oncol; 2023 Oct; 41(10):395-397. PubMed ID: 37833099
[TBL] [Abstract][Full Text] [Related]
14. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.
Powles T; Walker J; Andrew Williams J; Bellmunt J
Cancer Treat Rev; 2020 Jan; 82():101925. PubMed ID: 31785413
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.
Kardoust Parizi M; Enikeev D; Glybochko PV; Seebacher V; Janisch F; Fajkovic H; Chłosta PL; Shariat SF
World J Urol; 2020 Jun; 38(6):1437-1449. PubMed ID: 31493109
[TBL] [Abstract][Full Text] [Related]
16. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.
Tsimafeyeu I; Tjulandin S
BJU Int; 2019 Apr; 123(4):563-565. PubMed ID: 30457694
[No Abstract] [Full Text] [Related]
17. S100P as a Marker for Urothelial Histogenesis: A Critical Review and Comparison With Novel and Traditional Urothelial Immunohistochemical Markers.
Suryavanshi M; Sanz-Ortega J; Sirohi D; Divatia MK; Ohe C; Zampini C; Luthringer D; Smith SC; Amin MB
Adv Anat Pathol; 2017 May; 24(3):151-160. PubMed ID: 28398953
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
[TBL] [Abstract][Full Text] [Related]
19. Update on Flat and Papillary Urothelial Lesions: Genitourinary Pathology Society Consensus Recommendations.
Compérat E; Oszwald A; Wasinger G; Shariat S; Amin M
Surg Pathol Clin; 2022 Dec; 15(4):629-640. PubMed ID: 36344180
[TBL] [Abstract][Full Text] [Related]
20. The many faces of urothelial carcinoma: an update with an emphasis on recently described variants.
Nigwekar P; Amin MB
Adv Anat Pathol; 2008 Jul; 15(4):218-33. PubMed ID: 18580098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
